Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 204-210

  Ochi, Hidenori ^a,b,c   Hayes, C Nelson ^a,b,c   Abe, Hiromi ^a,b,c   Hayashida, Yasufumi ^a,b,c   Uchiyama, Tomotaka ^a   Kamatani, Naoyuki ^a   Nakamura, Yusuke ^d   Chayama, Kazuaki ^a,b,c  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; IL28B GENE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; ROC CURVE; VIRAL LOAD; YOUNG ADULT;

EID: 84555189205     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir726     Document Type: Article

References (44)

1. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26:15S-20S.
2. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351-5.
3. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31:9-16. (Pubitemid 30002685)
4. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
5. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol 2007; 13:2461-6. (Pubitemid 46929502)
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
7. Fowell AJ, Nash KL. Telaprevir: A new hope in the treatment of chronic hepatitis C? Adv Ther 2010; 27:512-22.
8. Morgan TR, O'Brien TR. IL28B-genotype testing now and in the era of direct-acting antiviral agents. Clin Gastroenterol Hepatol 2011; 9:293-4.
9. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204:84-93.
10. Kogure T, Ueno Y, Fukushima K, et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 14:7225-30.
11. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54:1317-24.
12. Watanabe S, Enomoto N, Koike K, et al. PERFECT Study Group. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2010; 40:135-44.
13. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-41. (Pubitemid 40585366)
14. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-64; quiz 214-7. (Pubitemid 43049856)
15. Gopal K, Johnson TC, Gopal S, et al. Correlation between betalipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44:335-40. (Pubitemid 44214872)
16. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46:403-10. (Pubitemid 46185701)
17. Bergmann JF, Vrolijk JM, van der Schaar P, et al. G-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27:1217-25. (Pubitemid 47543150)
18. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24:1003-9. (Pubitemid 26365895)
19. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49:634-51.
20. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
21. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
22. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9.
23. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
24. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-14.
25. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138:1338-45, 1345 e1-7.
26. Thompson AJ, Muir AJ, Sulkowski MS, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010; 139:120-9.
27. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52:421-9.
28. Fellay J, Thompson A, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-8.
29. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirininduced anemia and outcomes of therapyda genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139:1190-7, e3.
30. Thompson A, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139:1181-9.
31. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53:415-21.
32. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
33. Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40:8-13.
34. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis-diagnosis, grading and staging. Hepatology 1994; 19:1513-20. (Pubitemid 24166476)
35. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46:471-7. (Pubitemid 32744120)
36. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explorations 2009; 11:10-18.
37. Maiellaro PA, Cozzolongo R, Marino P. Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Curr Pharm Des 2004; 10:2101-9. (Pubitemid 38842654)
38. Wang CH, Mo LR, Lin RC, Kuo JJ, Chang KK, Wu JJ. Artificial neural network model is superior to logistic regression model in predicting treatment outcomes of interferon-based combination therapy in patients with chronic hepatitis C. Intervirology 2008; 51:14-20.
39. Lin E, Hwang Y, Wang SC, Gu ZJ, Chen EY. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 2006; 7:1017-24. (Pubitemid 44644781)
40. Lin E, Hwang Y. A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy. Mol Diagn Ther 2008; 12:219-23.
41. Kurosaki M, Sakamoto N, Iwasaki M, et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011; 46:401-9.
42. Kurosaki M, Matsunaga K, Hirayama I, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40:251-60.
43. Medrano J, Neukam K, Rallon N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51:1209-16.
44. O'Brien TR, Everhart JE, Morgan TR, et al. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011; 6:e20904.